Europe – Page 74 – pharmaceutical daily

June 19, 2019 Off

Natural ingredients show beneficial effects on cardiovascular health and sports performance

Euromed, a Spain-based producer of standardized herbal extracts and natural active substances for pharmaceutical, nutraceutical and cosmetic industries, said Wednesday that, according to a recently published randomised, double-blind, placebo-controlled study, supplementation with Euromed’s natural extracts Pomanox™ and Mediteanox™ could help to maintain a healthy blood pressure, endothelial function and levels of circulating oxidised low-density lipoprotein cholesterol (oxLDL).

June 19, 2019 Off

Lynparza approved in Japan for 1st-line maintenance therapy in BRCA-mutated advanced ovarian cancer

By Dino Mustafić

AstraZeneca and Merck revealed Wednesday that Lynparza (olaparib) has been approved in Japan as a maintenance treatment after 1st-line chemotherapy in patients with BRCA-mutated (BRCAm) advanced ovarian cancer, the only PARP inhibitor approved in Japan .

June 19, 2019 Off

The approval of BRACAnalysis for women with ovarian cancer in Japan

By Dino Mustafić

Japanese Ministry of Health, Labour, and Welfare has granted a second manufacturing and marketing approval for Myriad Genetics’ subsidiary, Myriad Genetic Laboratories, for BRACAnalysis Diagnostic System as a companion diagnostic with the PARP inhibitor, Lynparza, marketed by AstraZeneca and Merck.

June 19, 2019 Off

Uterine Fibroids Market Spotlight, 2026 – Repros Therapeutics has the Highest Number of Completed Clinical Trials

By BusinessWire

It is estimated that there were approximately 92.2
million prevalent cases of uterine fibroids worldwide in females aged
15 years and over, and forecasts that number to increase to 102.7
million prevalent cases by 2026.

June 19, 2019 Off

Global Peripheral T-Cell Lymphoma (PTCL) Market Spotlight 2018-2026

By BusinessWire

Estimation says that in 2017, there were approximately 19,950
incident cases of peripheral T-cell lymphoma (PTCL) worldwide, and
forecasts that number to increase to 23,880 incident cases by 2026.

June 19, 2019 Off

Parasitic Diseases Therapeutics Market Worth USD 1.79 Billion, at 5% CAGR During 2019-2023

By BusinessWire

Therapeutics Market by type (antiprotozoal therapeutics, anthelminthic
therapeutics, scabicides, and pediculicides therapeutics) and geographic
regions (Asia, ROW, North America, and Europe) is witnessed to
grow USD 1.79 billion, at a CAGR of 5% from 2019 to 2023”

June 19, 2019 Off

ObsEva clears issues with FDA over nolasiban

By Dino Mustafić

ObsEva’s has recently cleared with the U.S. Food and Drug Administration (FDA) several important development issues for its oral oxytocin receptor antagonist nolasiban, which enables it to begin its U.S. Phase 3 clinical trial (IMPLANT 3) in the fourth quarter of this year or early 2020.

June 18, 2019 Off

Novigenix welcomes to the Board doctor Francois Martelet, as Non-Executive Director

By BusinessWire

Novigenix SA, a leading Immuno-Transcriptomics company that develops and
commercializes products for early cancer detection and precision
medicine, today announced the appointment of Francois Martelet, M.D., to
its Board of Directors as a non-executive director. Dr. Martelet has
over 25 years’ experience at both corporate and operational level in
pharmaceutical and biotech companies.

June 17, 2019 Off

Arena Pharmaceuticals testing etrasimod’s potential as an important future therapy for ulcerative colitis

By Dino Mustafić

Arena Pharmaceuticals has dosed first patients in a trial called ELEVATE UC 52, which is the first of two pivotal trials within the Phase 3 registrational program designated to test etrasimod 2 mg in subjects with moderately to severely active ulcerative colitis (UC).

May 29, 2019 Off

FDA grants supplemental nda for Allergan, Gedeon Richter’s Vraylar

By Dino Mustafić

Allergan and Gedeon Richter got the U.S. Food and Drug Administration approval for a supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine) for expanded use to treat depressive episodes associated with bipolar I disorder (bipolar depression) in adults.